Cardiocirculatory, biochemical and hemostatic evaluation of dogs with hyperadrenocorticism at diagnosis and after treatment.
10.14405/kjvr.2016.56.3.161
- Author:
Frederico Aécio CARVALHO SOARES
1
;
Juliana Pereira MATHEUS
;
Guilherme Luiz CARVALHO
;
Elisa Barp NEUWALD
;
Alan GOMES PÖPPL
;
Stella Faria VALLE
;
Félix Hilário Diaz GONZÁLEZ
Author Information
1. School of Veterinary Medicine, Centro Universitario Ritter dos Reis-UniRitter, Porto Alegre 90840-440, Brazil. fredaecio@gmail.com
- Publication Type:Original Article
- Keywords:
canine;
cardiac troponin I;
cardiology;
endocrinology;
trilostane
- MeSH:
Adrenocortical Hyperfunction*;
Animals;
Blood Pressure;
Cardiology;
Diagnosis*;
Dogs*;
Echocardiography, Doppler;
Electrocardiography;
Endocrinology;
Hypertension;
Troponin I
- From:Korean Journal of Veterinary Research
2016;56(3):161-166
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hyperadrenocorticism (HAC) is a common endocrinopathy among dogs that causes multisystemic signs. This study was conducted to evaluate cardiocirculatory, biochemical, and hemostatic parameters in dogs with HAC at diagnosis, in addition to verifying whether abnormal parameters could be controlled by initial treatment with trilostane. Fifteen dogs with HAC were assessed by systolic blood pressure measurement, electrocardiography, Doppler echocardiography, serum concentration of troponin I, and biochemical and hemostatic profile at diagnosis and after trilostane therapy. Unlike biochemical parameters, hemostatic and cardiocirculatory parameters were not significantly influenced by the onset of treatment. The authors believe that clinical treatment with trilostane for 3 to 4 months might not be sufficient for the stabilization of cardiocirculatory abnormalities such as hypertension. Therefore, dogs with HAC must receive cardiocirculatory monitoring at diagnosis and during drug treatment.
